Q&A: NCI's Henry Rodriguez Says CPTC's Second Phase Will Focus on Applications
July 09, 2010
Q&A: NCI's Henry Rodriguez Says CPTC's Second Phase Will Focus on Applications
ProteoMonitor spoke to Henry Rodriguez, director of the Clinical Proteomic Technologies for Cancer program at NCI, about the recently announced reissuance of funds for the CPTC and what direction the initiative's research will take going forward.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- NCI CPTC Annual Meeting Features Call for Near-Term Clinical Applications, Focus on PTMs
September 10, 2010 / ProteoMonitor - New Mock 510(k) Submission Guides Aim to Help Navigate FDA's Protein IVDMIA Review Process
January 15, 2010 / ProteoMonitor - NCI Kicks Off Second Stage of Clinical Proteomic Technologies for Cancer Initiative
August 26, 2011 / ProteoMonitor - Lung Cancer Study Highlights Current Limitations of MALDI Mass Spec
July 22, 2011 / ProteoMonitor - Correlogic Developing 'Second Generation' OvaCheck; Seeks Ruling on Quest, LabCorp Licenses
July 8, 2011 / ProteoMonitor